[{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviko Radiopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Leo Cancer Care","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviko Radiopharmaceuticals \/ Leo Cancer Care","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Leo Cancer Care"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Neutron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Aviko Radiopharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : Aviko aims to advance the precision boron neutron capture therapy (BNCT), a precision medicine approach to treat cancer by destroying cancerous cells while minimizing the impact to surrounding healthy tissues.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : The partnership aims to advance boron neutron capture therapy (BNCT) to treat cancer. BNCT involves a non-toxic boron medicine that is designed to accumulate in cancer cells while being quickly cleared from normal tissues in the body.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 06, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Neutron Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : Under the partnership, companies will expand boron neutron capture therapy (BNCT) which involves an investigational non-toxic boron medicine that is designed to accumulate in cancer cells, as a potential treatment for different types of cancer.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Leo Cancer Care

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank